Article
Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration.
The pharmacogenomics journal - 1 Jun 2013
Fernandez-Rozadilla C, Cazier J B, Moreno V, Crous-Bou M, Guinó E, Durán G, Lamas M J, López R, Candamio S, Gallardo E, Paré L, Baiget M, Páez D, López-Fernández L A, Cortejoso L, García M I, Bujanda L, González D, Gonzalo V, Rodrigo L, Reñé J M, Jover R, Brea-Fernández A, Andreu M, Bessa X, Llor X, Xicola R, Palles C, Tomlinson I, Castellví-Bel S, Castells A, Ruiz-Ponte C, Carracedo A
Abstract excerpt
The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.